LATE CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AFTER COMPLETING LETERMOVIR PRIMARY PROPHYLAXIS – A SINGLE-CENTER PRELIMINARY ANALYSIS (EBMT 2026) - Feb 7, 2026 - Abstract #P174; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "Most recipients underwent allo-HCT due to acute leukaemia (AML–50, ALL–9) with use of myeloablative conditioning regimens in 59 (72%) procedures and in 73/81 (90%) transplants T-cell-depleting component (anti-thymocyte globulin or post-transplant cyclophosphamide) was applied...In 10 of 13 (77%) patients on ruxolitinib therapy any CMV late infection was diagnosed but only in 1 was csCMVi... Primary anti-CMV prophylaxis with LTV substantially reduced occurrence of csCMVi within the first 100 days after allo-HCT. However, any late CMV infection after completing LTV prophylaxis (beyond day +100) is diagnosed in a significant group of recipients (43% in our cohort). Selected risk factors for this complication could be characterized but further studies are needed to determine if and in whom extending the duration of primary LTV prophylaxis is beneficial."
Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation
|
|
Agnieszka Tomaszewska1; Kacprzyk Piotr1; Ewa Karakulska-Prystupiuk1; Joanna Drozd-Sokołowska1; Błażej Izdebski2; Piotr Boguradzki1; Kamila Skwierawska2; Katarzyna Pruszczyk-Matusiak2; Grzegorz Basak1
|